Correction: Arce-Huamani et al. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Medicina 2023, 59, 1867
Reference
- Arce-Huamani, M.A.; Barboza, J.J.; Martínez-Herrera, J.F.; Torres-Roman, J.S.; Maguiña, J.L. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Medicina 2023, 59, 1867. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Arce-Huamani, M.A.; Barboza, J.J.; Martínez-Herrera, J.F.; Torres-Roman, J.S.; Maguiña, J.L. Correction: Arce-Huamani et al. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Medicina 2023, 59, 1867. Medicina 2024, 60, 134. https://doi.org/10.3390/medicina60010134
Arce-Huamani MA, Barboza JJ, Martínez-Herrera JF, Torres-Roman JS, Maguiña JL. Correction: Arce-Huamani et al. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Medicina 2023, 59, 1867. Medicina. 2024; 60(1):134. https://doi.org/10.3390/medicina60010134
Chicago/Turabian StyleArce-Huamani, Miguel A., Joshuan J. Barboza, José Fabián Martínez-Herrera, J. Smith Torres-Roman, and Jorge L. Maguiña. 2024. "Correction: Arce-Huamani et al. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Medicina 2023, 59, 1867" Medicina 60, no. 1: 134. https://doi.org/10.3390/medicina60010134